AN2 Therapeutics' Q4 net loss widens on higher R&D expenses

Overview

• US biopharmaceutical firm's Q4 net loss widened yr/yr amid higher operating expenses

• Company secured $40 mln private placement in March 2026, extending cash runway into 2029

• AN2 advancing Phase 2 trials for polycythemia vera, M. abscessus lung disease, and Chagas disease

Outlook

• Company expects to initiate three Phase 2 studies in 2026, with data readouts into 2027

• AN2 plans to advance two oncology candidates into development in 2026

• Company projects cash runway into 2029 under current operating plan

Result Drivers

• HIGHER R&D SPENDING - Q4 R&D expenses rose yr/yr due to increased personnel, preclinical, research, chemistry manufacturing, and facilities costs, partially offset by lower clinical trial expenses after EBO-301 termination

• LOWER G&A EXPENSES - Q4 G&A expenses fell yr/yr due to decreased professional and personnel-related costs

• DECLINING INTEREST INCOME - Q4 interest income decreased yr/yr due to lower cash, cash equivalents and investment balances, and lower interest rates

Company press release: ID:nBw58vgJMa

Key Details

Analyst Coverage

• The one available analyst rating on the shares is "hold"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for AN2 Therapeutics Inc is $1.00, about 78.7% below its March 16 closing price of $4.69

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.